Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,361.28 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 29,088 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $7.06, for a total transaction of $205,361.28. Following the completion of the transaction, the insider owned 4,202,346 shares in the company, valued at approximately $29,668,562.76. The trade was a 0.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total transaction of $180,691.89.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Price Performance

NASDAQ:TRDA opened at $7.13 on Friday. Entrada Therapeutics, Inc. has a one year low of $5.02 and a one year high of $16.45. The company has a market cap of $277.62 million, a PE ratio of -1.80 and a beta of -0.25. The firm has a 50-day moving average of $7.06 and a 200-day moving average of $9.19.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The company had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. On average, equities research analysts expect that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TRDA has been the topic of several research analyst reports. Guggenheim cut their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Roth Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Entrada Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $17.75.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Entrada Therapeutics by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares during the last quarter. Rhumbline Advisers lifted its holdings in Entrada Therapeutics by 8.3% in the 2nd quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock worth $263,000 after buying an additional 2,982 shares during the period. American Century Companies Inc. grew its position in shares of Entrada Therapeutics by 10.8% in the 2nd quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after buying an additional 7,301 shares during the last quarter. Prudential Financial Inc. grew its position in shares of Entrada Therapeutics by 23.4% in the 2nd quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after buying an additional 5,370 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Entrada Therapeutics by 34.2% during the second quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock valued at $150,000 after buying an additional 5,702 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.